Immuneering applies bioinformatics via its proprietary Disease Cancelling Technology (DCT) platform to drive drug discovery and provide computational biology services to pharmaceutical and biotechnology companies. The company’s lead program, IMM-1-104, is a small-molecule MEK inhibitor in IND-enabling studies and was projected to enter clinical trials in late 2021. Immuneering also has additional preclinical programs in oncology, neuroscience, and immuno-oncology. The company announced an oversubscribed $62 million Series B financing to support its next growth phase. Proceeds will be used to advance programs to the clinical stage—particularly targets in the RAS/MAPK pathway—further develop the DCT platform, and enhance its computational biology services business. Immuneering is based in Cambridge, Massachusetts. Immuneering leverages bioinformatics and a proprietary Disease Cancelling Technology to engineer medicines that reverse disease signals across many relevant genes. Its pipeline targets cancer cachexia, next-generation KRAS inhibition, and the RAF-MEK pathway. The company also provides computational biology services to pharmaceutical and biotechnology companies. Led by co-founder and CEO Ben Zeskind, Ph.D., MBA, Immuneering aims to advance programs that have eluded conventional approaches, including metastasis-related indications. Immuneering intends to use new funding to advance its programs toward the clinic and to further develop its Disease Cancelling Technology and computational platforms.

Total raised

$82M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2021